Abstract: A liquid pressure control device includes a deformable part positioned in a deformed state between a housing and a case in an assembled state in which the housing and the case are assembled. When a first load is applied to the deformable part in a non-assembled state in which the case is separated further from the housing in a first direction than in the assembled state, the deformable part can place the housing and the case in a separation state in which a second end portion supported by a bottom wall is separated from a terminal in the first direction. When a second load greater than the first load is applied in the non-assembled state, the deformable part is deformed by the second load and can place the housing and the case in a contact state in which the second end portion and the terminal contact each other.

Abstract: A liquid pressure control device includes a deformable part positioned in a deformed state between a housing and a case in an assembled state in which the housing and the case are assembled. When a first load is applied to the deformable part in a non-assembled state in which the case is separated further from the housing in a first direction than in the assembled state, the deformable part can place the housing and the case in a separation state in which a second end portion supported by a bottom wall is separated from a terminal in the first direction. When a second load greater than the first load is applied in the non-assembled state, the deformable part is deformed by the second load and can place the housing and the case in a contact state in which the second end portion and the terminal contact each other.

Abstract: The present invention is directed to an irinotecan acid addition salt which is formed through addition of an acid selected from the group consisting of sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, citric acid, maleic acid, and succinic acid to irinotecan, to a method for producing the salt, and to a pharmaceutical composition containing the salt. The addition salt requires no heating process during drug preparation and provides an aqueous drug product in which the salt is stably dissolved.

Abstract: The present invention is to prepare efficiently 2?-amino-5?-hydroxypropiophenone corresponding to the AB-ring part of camptothecin (CPT) skeleton and a tricyclic ketone corresponding to the CDE-ring part in order to provide efficiently CPT by the total synthesis, which is a starting material for irinotecan hydrochloride and various kinds of camptothecin derivatives, and to provide stably CPT and its derivatives.

Abstract: The present invention is directed to an irinotecan acid addition salt which is formed through addition of an acid selected from the group consisting of sulfuric acid, nitric acid phosphoric acid, methanesulfonic acid, citric acid maleic acid and succinic acid to Irinotecan, to a method for producing the salt, and to a pharmaceutical composition containing the salt. The addition salt requires no heating process during drug preparation and provides an aqueous drug product in which the salt is stably dissolved.

Abstract: The present invention is to prepare efficiently 2?-amino-5?-hydroxypropiophenone corresponding to the AB-ring part of camptothecin (CPT) skeleton and a tricyclic ketone corresponding to the CDE-ring part in order to provide efficiently CPT by the total synthesis, which is a starting material for irinotecan hydrochloride and various kinds of camptothecin derivatives, and to provide stably CPT and its derivatives.

Abstract: The present invention is to prepare efficiently 2?-amino-5?-hydroxypropiophenone corresponding to the AB-ring part of camptothecin (CPT) skeleton and a tricyclic ketone corresponding to the CDE-ring part in order to provide efficiently CPT by the total synthesis, which is a starting material for irinotecan hydrochloride and various kinds of camptothecin derivatives, and to provide stably CPT and its derivatives.

Abstract: The present invention is to prepare efficiently 2′-amino-5′-hydroxypropiophenone corresponding to the AB-ring part of camptothecin (CPT) skeleton and a tricyclic ketone corresponding to the CDE-ring part in order to provide efficiently CPT by the total synthesis, which is a starting material for irinotecan hydrochloride and various kinds of camptothecin derivatives, and to provide stably CPT and its derivatives.